U.S. Pharmaceutical TV Ads: Pricing Information for Patients

At Janssen, we believe patients deserve a clearer picture of what they can expect to pay at the pharmacy counter. To help provide that clarity, we are voluntarily starting to include information about the cost of our prescription medicines in our TV advertising.

Based on what we heard from more than 2,000 consumers and patients, we will include the list price and typical patient out-of-pocket costs of our medicines in our TV ads via a simple visual representation.

We invite you to watch the video and read the information on this website to learn how we are sharing this information.

Janssen U.S. Direct-to-Consumer Disclosures Mar 2019 - web

Medicine Out-of-Pocket Range Supporting Information Additional Resources
XARELTO® (rivaroxaban) DTC-Page-Cost-Range-Image1.png The list price of XARELTO® is $448 per month, but most* patients pay between $0 and $47 per month. XARELTO® Website

XARELTO® Prescribing Information (including BOXED WARNING)
TREMFYA® (guselkumab) TREMFYA-priceline.png The list price of TREMFYA® is $5,430 per month, but most* patients pay between $0 and $16 a month. TREMFYA® Website

TREMFYA® Prescribing Information
STELARA® (ustekinumab) STELARA-priceline.png The list price of STELARA® is $11,002 per month, but most* patients pay between $0 and $5 a month. STELARA® Website

STELARA® Prescribing Information

*Actual out-of-pocket costs may vary based on dosing, site of care, insurance coverage, and your eligibility for support programs. Patients may not always pay the same amount per month, and some months may fall outside of this range due to insurance plan designs. Contact your insurance provider for more details on your individual plan. Out-of-pocket cost estimates are based on approved pharmacy claims, normalized to a 30-days’ supply, after application of insurance benefits. Costs do not include medical claims and starter kits. Estimates from IQVIA™ claims data (11/2017–10/2018; All rights reserved).